Videos

Thomas (TJ) Beadnell, Scientific Advisor at Eurofins Clinical Trial Solutions, shares key strategies for developing live cell assays for global clinical trials, focusing on logistics, antigen stability, and sample integrity to support reliable, high-quality results.

Chimeric antigen receptor (CAR) T cell therapy has transformed hematological cancer treatment, with six therapies now approved by the FDA. Four of these therapies (tisa-cel, axi-cel, brexu-cel, and liso-cel) target CD19 using single chain variable fragments (scFvs) derived from the heavy and light chain variable (VH and VL) regions of the monoclonal antibody FMC63.

Presented by Mark Wissel

Presented By Mark Wissel